Background: The emergence of COVID-19, stemming from SARS-CoV-2, has triggered a globalpandemic, urging rapid therapeutic interventions. Remdesivir, a nucleotide analog prodrug, garneredattention for its potential against COVID-19 due to in vitro efficacy against coronaviruses. This studyreviews Remdesivir’s adverse effects in COVID-19 patients. Methodology: while remdesivir shows promise, recent studies raise efficacy concerns. adverse drug event (ade) documentation is vital due to limited pre-pandemic ade data. who vigibase® analysis (2015-2020) and covid-19 ade studies were undertaken, focusing on age, severity, region, and organ impact. 1086 ades emerged from 439 case reports by july 19, 2020, in vigibase®, reducing to 1004 after duplicates were removed. ades primarily related to covid-19 patients (92.5%), notably from the americas (67.7%). mainly in males above 45, ades were serious (82.5%). key ades encompassed elevated hepatic enzymes (32.1%), renal damage (14.4%), increased creatinine levels (11.2%), and respiratory failure (6.4%). Conclusion: Liver and kidney function deterioration emerged as frequent ADEs, underscoring the need for vigilance during Remdesivir treatment. These findings align with regulatory documents. In sum, COVID-19 has prompted swift therapeutic responses, with Remdesivir being explored as a potential treatment. This study sheds light on associated ADEs, highlighting the importance of monitoring and informed decision-making
